bioMerieux (BMXMF)
OTHER OTC:BMXMF
BMXMF Stock Chart & Stats
$106.66
--
Market closed
$106.66
--
Day’s Range― - ―
52-Week Range$73.40 - $152.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)41.00
Market Cap
$9.04B
Enterprise Value$7.89B
Total Cash (Recent Filing)$569.80M
Total Debt (Recent Filing)$461.40M
Price to Earnings (P/E)19.8
Beta0.35
Next Earnings
Jul 28, 2026EPS Estimate
2.43Next Dividend Ex-DateN/A
Dividend Yield0.83%
Share Statistics
EPS (TTM)3.37
Shares Outstanding118,361,220
10 Day Avg. Volume67
30 Day Avg. Volume41
Financial Highlights & Ratios
PEG Ratio-4.00
Price to Book (P/B)3.17
Price to Sales (P/S)3.20
P/FCF Ratio28.72
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue1.94
Enterprise Value/Gross Profit3.65
Enterprise Value/Ebitda8.29
Forecast
1Y Price Target
$85.90Price Target Upside-19.46% Downside
Rating ConsensusHold
Number of Analyst Covering7
EPS Forecast (FY)5.06
Revenue Forecast (FY)$4.71B
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet And Low LeverageLow net leverage and a large equity base provide durable financial flexibility: the company can fund R&D, platform placements, and absorb cyclical softness without forced asset sales. This structural strength reduces solvency risk and supports long-term capital allocation choices across 2–6 months and beyond.
Consumables-driven Recurring Revenue ModelAn annuity-like consumables model creates durable revenue visibility as installed analyzers drive repeat reagent purchases. This structural pull-through supports margin stability and predictable cash flow, encouraging long-term customer relationships and smoothing revenue versus episodic instrument sales.
Improved Free Cash Flow Generation In 2025The step-up in free cash flow to ~€453M in 2025 signals better cash conversion and internal funding capacity. Sustained FCF supports reinvestment in test development, service networks, and potential shareholder returns while lowering dependence on external financing over the medium term.
Bears Say
Softening Revenue And Profitability TrendsA reversal from prior growth and peak margins reduces operating leverage and constrains reinvestment capacity. Persistent or renewed revenue decline would weaken consumable pull-through and pressure margin sustainability, making medium-term topline recovery critical to preserve durable earnings power.
Declining Return On Equity Versus Prior YearsA falling ROE indicates the company is generating less profit per unit of capital, implying either lower margin drivers or higher capital intensity. If the trend persists, it signals reduced efficiency of capital deployment and could limit long-term shareholder returns absent improvement in margins or growth.
Choppy Cash Conversion And Working-capital PressureIntermittent weak cash conversion suggests volatility in working-capital or receivable dynamics that can impair free cash flow generation even when earnings look stable. Persistent conversion issues reduce the reliability of internally generated funds for capex, R&D, or dividend continuity.
bioMerieux News
BMXMF FAQ
What was bioMerieux’s price range in the past 12 months?
bioMerieux lowest stock price was $73.40 and its highest was $152.00 in the past 12 months.
What is bioMerieux’s market cap?
bioMerieux’s market cap is $9.04B.
When is bioMerieux’s upcoming earnings report date?
bioMerieux’s upcoming earnings report date is Jul 28, 2026 which is in 33 days.
How were bioMerieux’s earnings last quarter?
bioMerieux released its earnings results on Feb 27, 2026. The company reported $2.28 earnings per share for the quarter, missing the consensus estimate of $2.423 by -$0.143.
Is bioMerieux overvalued?
According to Wall Street analysts bioMerieux’s price is currently Overvalued.
Does bioMerieux pay dividends?
bioMerieux pays a Annually dividend of $1.132 which represents an annual dividend yield of 0.83%. See more information on bioMerieux dividends here
What is bioMerieux’s EPS estimate?
bioMerieux’s EPS estimate is 2.43.
How many shares outstanding does bioMerieux have?
bioMerieux has 118,361,220 shares outstanding.
What happened to bioMerieux’s price movement after its last earnings report?
bioMerieux reported an EPS of $2.28 in its last earnings report, missing expectations of $2.423. Following the earnings report the stock price went up 2.168%.
Which hedge fund is a major shareholder of bioMerieux?
Currently, no hedge funds are holding shares in BMXMF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
bioMerieux
bioMérieux S.A. is a global entity operating across the Americas, Europe, the Middle East, Africa, and the Asia Pacific, specializing in the development and production of in vitro diagnostic solutions. The company's sophisticated systems utilize biological samples to identify infectious diseases, cardiovascular conditions, and various forms of cancer. Additionally, bioMérieux provides essential microbiological testing services for the manufacturing sectors, primarily serving the food, pharmaceutical, cosmetics, and veterinary industries. Its client base includes clinical and hospital laboratories, medical practitioners, blood banks, and industrial quality control facilities. Founded in 1963, originally under the name B-D Mérieux, bioMérieux S.A. maintains its headquarters in Marcy l'Etoile, France, and functions as a subsidiary of Institut Mérieux SA.
BMXMF Stock 12 Month Forecast
Average Price Target
$85.90
▼(-19.46% Downside)
Eurofins Scientific
―
Sartorius Stedim Biotech
―
Virbac SA
―
Eurofins-Cerep SA
―
Biosynex SA
―
Ownership Overview
―
Insiders
5.33% Mutual Funds
<0.01% Other Institutional Investors
90.64% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---